---
document_datetime: 2025-11-23 14:32:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/invirase.html
document_name: invirase.html
version: success
processing_time: 0.0959667
conversion_datetime: 2025-12-24 01:51:40.53636
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Invirase

[RSS](/en/individual-human-medicine.xml/65411)

##### Withdrawn

This medicine's authorisation has been withdrawn

saquinavir

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Invirase](#news-on)
- [More information on Invirase](#more-information-on-invirase-961)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 16 August 2023, the European Commission withdrew the marketing authorisation for Invirase (saquinavir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Roche Registration GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Invirase was granted marketing authorisation in the EU on 4 October 1996 for the treatment of HIV-1 infection. The marketing authorisation was initially valid for a 5-year period. It was granted unlimited validity in 2006.

The European Public Assessment Report (EPAR) for Invirase is updated to indicate that the marketing authorisation is no longer valid.

Invirase : EPAR - Summary for the public

English (EN) (190.67 KB - PDF)

**First published:** 01/12/2008

**Last updated:** 25/09/2023

[View](/en/documents/overview/invirase-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-624)

български (BG) (275.76 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/bg/documents/overview/invirase-epar-summary-public_bg.pdf)

español (ES) (193.02 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/es/documents/overview/invirase-epar-summary-public_es.pdf)

čeština (CS) (237.45 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/cs/documents/overview/invirase-epar-summary-public_cs.pdf)

dansk (DA) (188.78 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/da/documents/overview/invirase-epar-summary-public_da.pdf)

Deutsch (DE) (199.88 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/de/documents/overview/invirase-epar-summary-public_de.pdf)

eesti keel (ET) (182.53 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/et/documents/overview/invirase-epar-summary-public_et.pdf)

ελληνικά (EL) (288.57 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/el/documents/overview/invirase-epar-summary-public_el.pdf)

français (FR) (197.57 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/fr/documents/overview/invirase-epar-summary-public_fr.pdf)

hrvatski (HR) (223.26 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/hr/documents/overview/invirase-epar-summary-public_hr.pdf)

italiano (IT) (190.65 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/it/documents/overview/invirase-epar-summary-public_it.pdf)

latviešu valoda (LV) (240.33 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/lv/documents/overview/invirase-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (229.19 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/lt/documents/overview/invirase-epar-summary-public_lt.pdf)

magyar (HU) (215.94 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/hu/documents/overview/invirase-epar-summary-public_hu.pdf)

Malti (MT) (250.91 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/mt/documents/overview/invirase-epar-summary-public_mt.pdf)

Nederlands (NL) (195.17 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/nl/documents/overview/invirase-epar-summary-public_nl.pdf)

polski (PL) (231.77 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/pl/documents/overview/invirase-epar-summary-public_pl.pdf)

português (PT) (193.26 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/pt/documents/overview/invirase-epar-summary-public_pt.pdf)

română (RO) (234.06 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/ro/documents/overview/invirase-epar-summary-public_ro.pdf)

slovenčina (SK) (229.56 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/sk/documents/overview/invirase-epar-summary-public_sk.pdf)

slovenščina (SL) (224.18 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/sl/documents/overview/invirase-epar-summary-public_sl.pdf)

Suomi (FI) (186.69 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/fi/documents/overview/invirase-epar-summary-public_fi.pdf)

svenska (SV) (190.32 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

25/09/2023

[View](/sv/documents/overview/invirase-epar-summary-public_sv.pdf)

## Product information

Invirase : EPAR - Product Information

English (EN) (2.32 MB - PDF)

**First published:** 08/04/2009

**Last updated:** 25/09/2023

[View](/en/documents/product-information/invirase-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-907)

български (BG) (3.04 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/bg/documents/product-information/invirase-epar-product-information_bg.pdf)

español (ES) (2.3 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/es/documents/product-information/invirase-epar-product-information_es.pdf)

čeština (CS) (2.53 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/cs/documents/product-information/invirase-epar-product-information_cs.pdf)

dansk (DA) (2.34 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/da/documents/product-information/invirase-epar-product-information_da.pdf)

Deutsch (DE) (2.51 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/de/documents/product-information/invirase-epar-product-information_de.pdf)

eesti keel (ET) (2.1 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/et/documents/product-information/invirase-epar-product-information_et.pdf)

ελληνικά (EL) (3.33 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/el/documents/product-information/invirase-epar-product-information_el.pdf)

français (FR) (2.41 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/fr/documents/product-information/invirase-epar-product-information_fr.pdf)

hrvatski (HR) (2.5 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/hr/documents/product-information/invirase-epar-product-information_hr.pdf)

íslenska (IS) (2.64 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/is/documents/product-information/invirase-epar-product-information_is.pdf)

italiano (IT) (2.55 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/it/documents/product-information/invirase-epar-product-information_it.pdf)

latviešu valoda (LV) (2.88 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/lv/documents/product-information/invirase-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.68 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/lt/documents/product-information/invirase-epar-product-information_lt.pdf)

magyar (HU) (2.58 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/hu/documents/product-information/invirase-epar-product-information_hu.pdf)

Malti (MT) (2.86 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/mt/documents/product-information/invirase-epar-product-information_mt.pdf)

Nederlands (NL) (2.33 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/nl/documents/product-information/invirase-epar-product-information_nl.pdf)

norsk (NO) (2.25 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/no/documents/product-information/invirase-epar-product-information_no.pdf)

polski (PL) (3.25 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/pl/documents/product-information/invirase-epar-product-information_pl.pdf)

português (PT) (2.27 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/pt/documents/product-information/invirase-epar-product-information_pt.pdf)

română (RO) (2.91 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/ro/documents/product-information/invirase-epar-product-information_ro.pdf)

slovenčina (SK) (2.52 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/sk/documents/product-information/invirase-epar-product-information_sk.pdf)

slovenščina (SL) (2.48 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/sl/documents/product-information/invirase-epar-product-information_sl.pdf)

Suomi (FI) (2.33 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/fi/documents/product-information/invirase-epar-product-information_fi.pdf)

svenska (SV) (2.22 MB - PDF)

**First published:**

08/04/2009

**Last updated:**

25/09/2023

[View](/sv/documents/product-information/invirase-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0139 10/03/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Invirase : EPAR - All Authorised presentations

English (EN) (59.87 KB - PDF)

**First published:** 31/10/2006

**Last updated:** 25/09/2023

[View](/en/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-920)

български (BG) (78.96 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/bg/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_bg.pdf)

español (ES) (60.68 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/es/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_es.pdf)

čeština (CS) (114.55 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/cs/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.48 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/da/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (59.9 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/de/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (62.07 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/et/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (80.34 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/el/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_el.pdf)

français (FR) (60.7 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/fr/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (107.85 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/hr/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (75.34 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/is/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_is.pdf)

italiano (IT) (75.57 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/it/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (66.85 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/lv/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (78.09 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/lt/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (82.58 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/hu/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (77.3 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/mt/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (60.41 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/nl/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (60.91 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/no/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_no.pdf)

polski (PL) (128.88 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/pl/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_pl.pdf)

português (PT) (63.05 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/pt/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_pt.pdf)

română (RO) (72.48 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/ro/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (75.36 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/sk/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (74.96 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/sl/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (57.99 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/fi/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59.77 KB - PDF)

**First published:**

31/10/2006

**Last updated:**

25/09/2023

[View](/sv/documents/all-authorised-presentations/invirase-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Invirase Active substance saquinavir International non-proprietary name (INN) or common name saquinavir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AE01

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.

## Authorisation details

EMA product number EMEA/H/C/000113 Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1

Opinion adopted 23/07/2009 Marketing authorisation issued 03/10/1996 Withdrawal of marketing authorisation 16/08/2023 Revision 50

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Invirase : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (3.81 MB - PDF)

**First published:** 08/04/2009

**Last updated:** 25/09/2023

[View](/en/documents/procedural-steps-after/invirase-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Invirase-H-C-113-P46-54 : EPAR - Assessment Report

Adopted

Reference Number: EMA/129533/2013

English (EN) (299.64 KB - PDF)

**First published:** 08/04/2013

**Last updated:** 25/09/2023

[View](/en/documents/variation-report/invirase-h-c-113-p46-54-epar-assessment-report_en.pdf)

Invirase-H-C-113-A20-88 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/58070/2011

English (EN) (823.18 KB - PDF)

**First published:** 30/03/2011

**Last updated:** 25/09/2023

[View](/en/documents/variation-report/invirase-h-c-113-a20-88-epar-assessment-report-article-20_en.pdf)

Invirase-H-C-113-II-85: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/623173/2010

English (EN) (668.93 KB - PDF)

**First published:** 13/10/2010

**Last updated:** 25/09/2023

[View](/en/documents/variation-report/invirase-h-c-113-ii-85-epar-assessment-report-variation_en.pdf)

Invirase-H-C-113-II-62 : EPAR - Assessment Report - Variation

English (EN) (100.65 KB - PDF)

**First published:** 07/08/2008

**Last updated:** 25/09/2023

[View](/en/documents/variation-report/invirase-h-c-113-ii-62-epar-assessment-report-variation_en.pdf)

Invirase-H-C-113-X-43 : EPAR - Assessment Report - Extension

English (EN) (688.77 KB - PDF)

**First published:** 31/10/2006

**Last updated:** 25/09/2023

[View](/en/documents/variation-report/invirase-h-c-113-x-43-epar-assessment-report-extension_en.pdf)

Invirase : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (237.23 KB - PDF)

**First published:** 31/10/2006

**Last updated:** 25/09/2023

[View](/en/documents/steps-after-cutoff/invirase-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Committee for medicinal products for human use, summary of positive opinion for Lamivudine Teva

Reference Number: EMEA/CHMP/436960/2009

English (EN) (57.42 KB - PDF)

**First published:** 23/07/2009

**Last updated:** 25/09/2023

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-lamivudine-teva_en.pdf)

Invirase : EPAR - Scientific Discussion

English (EN) (1.07 MB - PDF)

**First published:** 31/10/2006

**Last updated:** 25/09/2023

[View](/en/documents/scientific-discussion/invirase-epar-scientific-discussion_en.pdf)

Invirase : EPAR - Procedural steps taken before authorisation

English (EN) (134.5 KB - PDF)

**First published:** 31/10/2006

**Last updated:** 25/09/2023

[View](/en/documents/procedural-steps/invirase-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Invirase

[Updated advice on body fat changes and lactic acidosis with HIV medicines](/en/news/updated-advice-body-fat-changes-lactic-acidosis-hiv-medicines) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

[European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection](/en/news/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection) 19/11/2013

[European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations](/en/news/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations) 23/10/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 18-21 October 2010](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-october-2010) 22/10/2010

[European Medicines Agency concludes that benefit-risk balance of Invirase remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-invirase-remains-positive) 21/10/2010

#### More information on Invirase

Questions and answers on the review of Invirase (saquinavir)

Reference Number: EMEA/H/C/113/A-20/0088

English (EN) (58.34 KB - PDF)

**First published:** 21/10/2010

**Last updated:** 21/10/2010

[View](/en/documents/other/questions-and-answers-review-invirase-saquinavir_en.pdf)

**This page was last updated on** 25/09/2023

## Share this page

[Back to top](#main-content)